Reaction
Metastases To Abdominal Cavity reporting signals
As of the last recalculation, Metastases To Abdominal Cavity appears in 488 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is LANREOTIDE ACETATE (PRR 66.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lanreotide Acetate | 12 | 66.9 | 67.0 |
| Regorafenib | 14 | 52.9 | 53.0 |
| Octreotide Acetate | 35 | 52.4 | 52.5 |
| Loperamide Hydrochloride Oral | 10 | 42.6 | 42.7 |
| Loperamide Hcl | 11 | 37.3 | 37.3 |
| Everolimus Tablets | 14 | 36.6 | 36.7 |
| Everolimus | 37 | 33.5 | 33.5 |
| Olaparib | 15 | 31.5 | 31.5 |
| Exemestane | 15 | 30.8 | 30.8 |
| Sorafenib | 14 | 29.6 | 29.6 |
| Niraparib | 11 | 21.6 | 21.6 |
| Gemcitabine | 16 | 17.9 | 17.9 |
| Cabozantinib | 19 | 17.5 | 17.5 |
| Panitumumab | 6 | 16.5 | 16.5 |
| Docetaxel Anhydrous | 23 | 15.2 | 15.2 |
| Docetaxel | 23 | 15.2 | 15.2 |
| Temozolomide | 7 | 14.4 | 14.4 |
| Pazopanib Hydrochloride | 8 | 12.8 | 12.8 |
| Durvalumab | 5 | 10.6 | 10.6 |